12/17
09:15 am
xbio
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Medium
Report
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
12/16
09:27 am
xbio
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform [Yahoo! Finance]
Low
Report
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform [Yahoo! Finance]
12/16
09:00 am
xbio
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Medium
Report
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
12/5
12:56 pm
xbio
Xenetic Biosciences Inc (NASDAQ: XBIO) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Xenetic Biosciences Inc (NASDAQ: XBIO) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
12/5
09:03 am
xbio
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program [Yahoo! Finance]
Low
Report
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program [Yahoo! Finance]
12/5
08:45 am
xbio
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Medium
Report
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
11/22
09:26 am
xbio
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment [Yahoo! Finance]
Low
Report
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment [Yahoo! Finance]
11/22
09:15 am
xbio
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Low
Report
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
11/22
08:13 am
xbio
Xenetic Biosciences Inc (NASDAQ: XBIO) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
High
Report
Xenetic Biosciences Inc (NASDAQ: XBIO) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
11/21
08:48 am
xbio
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis [Yahoo! Finance]
Medium
Report
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis [Yahoo! Finance]
11/21
08:30 am
xbio
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Medium
Report
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
11/13
08:30 am
xbio
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
High
Report
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
11/12
09:00 am
xbio
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Medium
Report
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
11/7
09:00 am
xbio
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Low
Report
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
10/22
09:21 am
xbio
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 [Yahoo! Finance]
Medium
Report
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 [Yahoo! Finance]
10/22
08:45 am
xbio
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Low
Report
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
10/17
09:02 am
xbio
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform [Yahoo! Finance]
Low
Report
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform [Yahoo! Finance]
10/17
08:30 am
xbio
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Medium
Report
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform